Pre-made Pepinemab benchmark antibody ( Whole mAb, anti-SEMA4D therapeutic antibody, Anti-A8/BB18/C9orf164/CD100/COLL4/GR3/M-sema-G/SEMAJ/coll-4 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-437

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-437 Category Tag

Product Details

Pre-Made Pepinemab biosimilar, Whole mAb, Anti-SEMA4D Antibody: Anti-A8/BB18/C9orf164/CD100/COLL4/GR3/M-sema-G/SEMAJ/coll-4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Pepinemab is a humanised IgG4 monoclonal antibody against the semaphorin 4D (SEMA4D; CD100), being developed by Vaccinex for the treatment of multiple cancers, Alzheimer’s disease and Huntington’s disease.

Products Name (INN Index)

Pre-Made Pepinemab biosimilar, Whole mAb, Anti-SEMA4D Antibody: Anti-A8/BB18/C9orf164/CD100/COLL4/GR3/M-sema-G/SEMAJ/coll-4 therapeutic antibody

INN Name

Pepinemab

Target

SEMA4D

Format

Whole mAb

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG4

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2018

Companies

Bristol-Myers Squibb,Children's Oncology Group,Emory University,Merck KGaA,National Cancer Institute (USA),Teva Pharmaceutical Industries,UCLAs Jonsson Comprehensive Cancer Center,Vaccinex

Conditions Approved

NA

Conditions Active

Huntington's disease,Non-small cell lung cancer,Osteosarcoma,Solid tumours,Colorectal cancer,Head and neck cancer,Malignant melanoma,Pancreatic cancer

Conditions Discontinued

Multiple sclerosis

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

SEMA4D

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide